The short answer
Avoid taking an oral zinc supplement at the same time as risedronate until your pharmacist confirms the schedule. Zinc is considered through the mineral-cation concern, but a direct zinc-risedronate clinical trial was not identified. This is a cautious application of product instructions, not a measured zinc-specific risk.
What this answer covers
Oral zinc-containing supplements with oral risedronate. The inference concerns supplemental mineral exposure, not all food, topical zinc or every chemical form.
- Supplement or preparation
- Zinc
- Medication ingredient
- risedronate
Why does this combination need attention?
Immediate-release labeling warns that oral products containing divalent cations interfere with absorption. Zinc is assessed through that category rather than a named zinc trial. Atelvia labeling names calcium, antacids, magnesium and iron, without a zinc-specific study. The class-based inference therefore should not be mistaken for quantified exact-pair clinical evidence.
How should the doses be scheduled?
For standard immediate-release risedronate, take the medicine before breakfast with plain water and observe the initial 30-minute wait before food or oral products. The labels additionally place calcium, antacids, magnesium and iron at another time of day. Atelvia is instead taken immediately after breakfast. Confirm the formulation before applying either routine; delayed release does not remove the mineral separation instructions.
What should I discuss with my pharmacist?
Check whether the zinc product also contains calcium, magnesium or iron; those ingredients have explicit risedronate separation instructions. Keep treatment for diagnosed zinc deficiency distinct from optional supplementation, and review total intake before changing a necessary product. If the schedule is unclear, ask your pharmacist rather than changing the osteoporosis medicine.
What are the limits of the evidence?
A mineral-class mechanism makes separation reasonable but does not establish the effect of zinc sulfate, gluconate or oxide individually. The risedronate formulation trial kept calcium and vitamin D at another meal and cannot resolve zinc-specific compatibility. No measured treatment-failure rate, added toxicity or guaranteed safe same-time dose can be given.
Evidence and practical considerations
Absorption & effectiveness
Avoid taking an oral zinc supplement at the same time as risedronate until your pharmacist confirms the schedule. Zinc is considered through the mineral-cation concern, but a direct zinc-risedronate clinical trial was not identified. This is a cautious application of product instructions, not a measured zinc-specific risk.
- Exact scope
- Oral zinc-containing supplements with oral risedronate. The inference concerns supplemental mineral exposure, not all food, topical zinc or every chemical form. with oral immediate-release risedronate sodium; oral delayed-release risedronate sodium
- Medication form and route
- oral immediate-release risedronate sodium; oral delayed-release risedronate sodium
- Timing or duration
- Timing applies on each prescribed oral dose day. Nutrient adequacy is an ongoing treatment consideration. Clinical trial durations and limitations are recorded in each source.
What remains uncertain
- A mineral-class mechanism makes separation reasonable but does not establish the effect of zinc sulfate, gluconate or oxide individually. The risedronate formulation trial kept calcium and vitamin D at another meal and cannot resolve zinc-specific compatibility. No measured treatment-failure rate, added toxicity or guaranteed safe same-time dose can be given.
Factors that may matter: Medication route and release formulation; Supplement mineral content and chemical preparation; Timing relative to breakfast and other oral products.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients taking immediate-release oral risedronate sodium tablets for approved bone indications.
The medicine is taken before breakfast and other oral products with an initial 30-minute interval. Calcium, antacids, magnesium products and iron are scheduled at a different time of day. Calcium and vitamin D adequacy is recommended, with supplementation if dietary intake is inadequate.
How this applies: Zinc is assessed by a divalent/mineral-cation class inference, not a named zinc trial in this label. No zinc-specific magnitude or universal salt equivalence is asserted. Exact scope: Oral zinc-containing supplements with oral risedronate. The inference concerns supplemental mineral exposure, not all food, topical zinc or every chemical form.
Product instructions and class-based absorption precautions do not quantify every individual mineral salt. They must not be substituted for delayed-release dosing instructions.
Source 2: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Postmenopausal women receiving delayed-release oral risedronate 35 mg; absorption crossover included 101 postmenopausal women.
Co-administration of the combination supplement reduced risedronate exposure approximately 38%. The label places calcium, antacids, magnesium products and iron at a different time of day and specifies Atelvia immediately after breakfast.
How this applies: Zinc is assessed by a divalent/mineral-cation class inference, not a named zinc trial in this label. No zinc-specific magnitude or universal salt equivalence is asserted. Exact scope: Oral zinc-containing supplements with oral risedronate. The inference concerns supplemental mineral exposure, not all food, topical zinc or every chemical form.
The absorption study used a combined calcium-vitamin D product and cannot isolate vitamin D, another mineral or every calcium salt. The 38% estimate is not transferable to all formulations or supplements.
Source 3: peer-reviewed randomized clinical trial
europepmc.org · Source check Sep 10, 2026
Population: 922 treated postmenopausal women with osteoporosis; immediate-release daily group n=307, delayed-release before-breakfast n=308 and after-breakfast n=307.
Delayed-release regimens were non-inferior on lumbar-spine bone mineral density. The supplement instructions deliberately separated calcium and vitamin D from risedronate.
How this applies: Direct evidence for risedronate formulation schedules, with separated calcium/vitamin D use. It does not test simultaneous zinc co-administration. Exact scope: Oral zinc-containing supplements with oral risedronate. The inference concerns supplemental mineral exposure, not all food, topical zinc or every chemical form.
Formulation efficacy study, not a simultaneous mineral co-administration trial. All subjects received supplements; their necessity, independent effects and optimal individual doses were not randomized. The older before-breakfast trial arm does not override current Atelvia after-breakfast instructions.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current oral formulation labels, route boundaries and original dosing evidence assessed. Exact existing statements adjudicated and article prepared. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: 8fbd762e612eb838
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.